Peter Mollys PHD thesis recognised Aussie biotechs are under valued compared to US. So whatever strategy is used it makes sense at sometime that US dual listing to maximise shareholder returns.
Timing is key we would want a complete data package / accelerated pathways to approval and perhaps partner agreement so it lights up. Just listing now IMO is too early so cost would outweigh benefit, revisit later in 2023.
Ann: Ethics submission to commence cardioprotection trial, page-19
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.040(2.35%) |
Mkt cap ! $282.9M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.66 | $35.93K | 21.54K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 8423 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 900 | 2 |
View Market Depth
| Last trade - 11.16am 18/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |